Improved survival rates for mitral valve heart surgery patients

May 10, 2012

Patients with mitral regurgitation, a type of valvular heart disease common in the elderly, are living longer after surgery, Yale School of Medicine researchers report in the journal Circulation: Cardiovascular Quality and Outcomes.

Surgery that replaces or repairs the mitral valve remains the definitive therapy for symptomatic mitral regurgitation, but surgery carries considerable risks of mortality and complications such as infection and renal failure. Led by John A. Dodson, M.D., a postdoctoral fellow in cardiology and geriatrics at Yale School of Medicine, the researchers found that short- and long-term mortality decreased in all subgroups of age, sex, and race, although it remained higher in female and non-white patients compared with male and white patients in all years studied.

Dodson and his team represent the NIH Heart, Lung and Blood Institute Center for Cardiovascular Outcomes Research (CCOR) at Yale University as well as the Yale University School of Medicine. They analyzed the 30-day and one-year mortality rate in 157,032 U.S. Medicare fee-for-service patients 65 years or older undergoing mitral valve surgery from 1999 to 2008.

"Mortality declined significantly at both 30 days and one year," said Dodson. "30-day mortality decreased from 8.1% to 4.2% from 1999 to 2008, a relative decline of 48%, while one-year mortality decreased from 15.3% in 1999 to 9.2% in 2008, a relative decline of 40%."

Dodson added that the overall rate of mitral valve surgery declined by 9% during the study period. Patients who were very elderly -- 85 years of age or older -- made up an increasing proportion of all patients undergoing mitral valve surgery (8.8% in 1999 to 12.7% in 2008). Surgery was also more commonly performed in male and white patients than in female and nonwhite patients.

"The marked reduction in mortality after mitral valve surgery over time is an encouraging trend for cardiac surgery," said Dodson. "Although our study was not designed to identify causes for the reduction in mortality, several factors may be responsible, including improved surgical techniques, and lower rates of post-operative complications."

"There remain differences in the rate of mitral valve surgery performed, and mortality outcomes, among sex and race subgroups that deserve further investigation," he added.

Dodson has been nominated for an American Heart Association Quality of Care and Outcomes Research (QCOR) Young Investigator Abstract Award, and the publication his paper is timed to coincide with his presentation at the QCOR meeting.
-end-
Other authors on the study included Yun Wang, Mayur M. Desai, Jose Augusto-Filho, Lissa Sugeng, Sabet W. Hashin and Harlan M. Krumholz.

The study was funded by the National Institute on Aging, and the National Heart, Lung, and Blood Institute.

doi: 10.1161/CIRCOUTCOMES.112.966077

Yale University

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.